INFO & CONTACTS:  +39 02 2390 1

A Randomized Phase 2/3 Study of BMS-986504 in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion

Phase: Phase I-II clinical trials

Principal Investigator: Dott.ssa Proto Claudia

Main Facility: Oncologia Medica Toraco-Polmonare

Drug: BMS-986504

Pathologies: Lung cancer

ClinicalTrials.gov: Read the details about clinical trials

This is a global Phase 2/3 clinical trial in patients with metastatic non-small cell lung cancer (NSCLC) harboring a homozygous MTAP deletion. The study is designed to evaluate the safety and efficacy of a new investigational agent, BMS-986504, administered in combination with pembrolizumab and chemotherapy, compared with the current standard treatment consisting of pembrolizumab plus chemotherapy.

Participants will be randomly assigned (1:1 randomization) to one of two treatment arms to compare the investigational treatment with the standard of care.

Arm A (Investigational Arm): BMS-986504 administered in combination with pembrolizumab and chemotherapy. BMS-986504 is a novel investigational agent designed to selectively target tumor cells harboring MTAP deletion, with the aim of enhancing the effectiveness of treatment.

Arm B (Control Arm): Placebo administered in combination with pembrolizumab and chemotherapy, which represents the current standard first-line treatment for this patient population.

The study is intended for patients with metastatic NSCLC who have not previously received systemic therapy for metastatic disease and whose tumors harbor a homozygous MTAP deletion. The primary objective of the study is to determine whether the addition of BMS-986504 to standard therapy can improve disease control and survival compared with standard therapy alone.

Last update: 16/07/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe